The article you requested is
Lupus Anticoagulant and Anticardiolipin Antibodies in Serum of Patients Treated With Risperidone
J Clin Psychiatry 2009;70(5):769-771 [letter]
Copyright 2009 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $40
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: In recent years, several studies reported an increased
rate of cerebrovascular events in patients treated with risperidone.
In April 2005, the U.S. Food and Drug Administration issued
a health advisory warning concerning an increased risk of
death among patients with dementia who were treated with
atypical antipsychotic agents.
Risperidone is a second-generation antipsychotic agent that
reportedly increases the blood level of glucose and alters
changes in lipid profiles.